EXELIXIS INC.

Lobbying for EXELIXIS INC.

Filing 4th Quarter - Amendment

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$510,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

S 1930
Small Biotech Innovation Act
HR 3731
Small Biotech Innovation Act

Lobbying activity 2

Health Issues

Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels.

Taxation/Internal Revenue Code

IRC Section 174 amortization of R&D expenditures.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.